[HTML][HTML] Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal

P Valent, C Akin, K Hartmann, I Alvarez-Twose… - …, 2021 - journals.lww.com
Mastocytosis is a hematologic neoplasm characterized by expansion and focal
accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone …

[HTML][HTML] Carbohydrate-based drugs launched during 2000− 2021

X Cao, X Du, H Jiao, Q An, R Chen, P Fang… - … Pharmaceutica Sinica B, 2022 - Elsevier
Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

EJ Duncavage, A Bagg, RP Hasserjian… - Blood, The Journal …, 2022 - ashpublications.org
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases

P Kolkhir, D Elieh-Ali-Komi, M Metz… - Nature Reviews …, 2022 - nature.com
Mast cells have crucial roles in allergic and other inflammatory diseases. Preclinical
approaches provide circumstantial evidence for mast cell involvement in many diseases, but …

[HTML][HTML] Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

DJ DeAngelo, DH Radia, TI George, WA Robinson… - Nature medicine, 2021 - nature.com
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT
D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) …

[HTML][HTML] Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

J Gotlib, A Reiter, DH Radia, MW Deininger… - Nature medicine, 2021 - nature.com
Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic
neoplasm characterized by mast cell infiltration and shortened survival. We report the results …

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

RM Stone, SJ Mandrekar, BL Sanford… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

P Valent, C Akin, DD Metcalfe - Blood, The Journal of the …, 2017 - ashpublications.org
Over the past few years, substantial advances have been made in understanding the
pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and …

[HTML][HTML] Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich's visions to precision medicine concepts

P Valent, C Akin, K Hartmann, G Nilsson, A Reiter… - Theranostics, 2020 - ncbi.nlm.nih.gov
The origin and functions of mast cells (MCs) have been debated since their description by
Paul Ehrlich in 1879. MCs have long been considered'reactive bystanders' and'amplifiers' in …

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

G Greiner, B Sprinzl, A Górska… - Blood, The Journal …, 2021 - ashpublications.org
Mastocytosis is a hematopoietic neoplasm characterized by expansion of KIT D816V-
mutated clonal mast cells in various organs and severe or even life-threatening anaphylactic …